Clearstead Advisors’s NovoCure NVCR Stock Holding History

Clearstead Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Buy	+66	New	+$999	﹤0.01%	2690
2026 Q1	–	Sell	-13	Closed	-$169	–	2662
2025 Q4	$169	Sell	13 -274	-95%	-$3.52K	﹤0.01%	2443
2025 Q3	$3.71K	Buy	+287	New	+$3.83K	﹤0.01%	2268
2023 Q3	–	Sell	-25	Closed	-$1.04K	–	1505
2023 Q2	$1.04K	Hold	25	–	–	﹤0.01%	1244
2023 Q1	$1.5K	Hold	25	–	–	﹤0.01%	1183
2022 Q4	$1.83K	Hold	25	–	–	﹤0.01%	1106
2022 Q3	$2K	Hold	25	–	–	﹤0.01%	1087
2022 Q2	$2K	Hold	25	–	–	﹤0.01%	1118
2022 Q1	$2K	Buy	25 +5	+25%	+$368	﹤0.01%	1219
2021 Q4	$2K	Hold	20	–	–	﹤0.01%	1123
2021 Q3	$2K	Hold	20	–	–	﹤0.01%	1140
2021 Q2	$4K	Hold	20	–	–	﹤0.01%	924
2021 Q1	$3K	Buy	20 +10	+100%	+$1.58K	﹤0.01%	925
2020 Q4	$2K	Hold	10	–	–	﹤0.01%	894
2020 Q3	$1K	Buy	+10	New	+$800	﹤0.01%	849

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Clearstead Advisors's NVCR Position: Q2 2026 in Review

Clearstead Advisors opened a new position in NovoCure (NVCR) in Q2 2026: 66 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2690 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in NVCR as recently as Q4 2025.

Clearstead Advisors first reported a position in NVCR in Q3 2020 and has held it in 15 quarters since. The position peaked at $4K in Q2 2021. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Clearstead Advisors held 66 shares of NovoCure worth $1K as of Q2 2026.
NovoCure was a new Clearstead Advisors position in Q2 2026.
NovoCure made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2690 holding.
Clearstead Advisors first reported a position in NovoCure in Q3 2020 and has held it in 15 quarters since.
Clearstead Advisors's NovoCure position peaked at $4K in Q2 2021.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.